United Therapeutics (UTHR) Non Operating Income (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Non Operating Income data on file, last reported at -$7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 118.43% year-over-year to -$7.5 million; the trailing twelve-month figure through Mar 2026 stood at $173.2 million (up 7.98% YoY), and the FY2025 full-year result was $221.4 million, up 36.67% from the prior year.
• Non Operating Income declined to -$7.5 million in Q1 2026, from $87.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $87.3 million in Q4 2025 to a low of -$51.2 million in Q2 2022.
• A 5-year average of $25.7 million and a median of $35.3 million in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income tumbled 798.25% in 2022 and jumped 1477.78% in 2023, its largest moves.
• Tracing UTHR's Non Operating Income over 5 years: stood at $3.2 million in 2022, then surged by 1003.12% to $35.3 million in 2023, then increased by 9.92% to $38.8 million in 2024, then soared by 125.0% to $87.3 million in 2025, then tumbled by 108.59% to -$7.5 million in 2026.
• Business Quant data shows UTHR's Non Operating Income at -$7.5 million in Q1 2026, $87.3 million in Q4 2025, and $49.5 million in Q3 2025.